Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax, Ivosidenib, and Azacitidine in IDH1-Mutated AML
NCT06611839Phase 2Recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Oct 2025
- Primary completion
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ivosidenib, venetoclax and azacitidine in acute myeloid leukemia (AML), sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoints: Composite Complete Remission Rate, Measurable Residual Disease Negative Rate by Flow Cytometry and 2 more. Started Oct 2025; status: recruiting.
02
Drugs
ivosidenibvenetoclaxazacitidine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT06611839.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06611839.